PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022
NEW YORK, Sept. 16, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01622995/PharmaPoint-Dry-Eye-Syndrome---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022
Summary
GlobalData has released its new Country report, "PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022". Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.
The DES market in India is projected to grow during the forecast period. During the forecast period, the primary market growth driver will be increased awareness of DES and overall improved access to medical care for India's enormous population.
Scope
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting India DES market.
Reasons to buy
- Stay ahead of the competition by understanding the changing competitive landscape for DES
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in India.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 12
3.1.3 Classification 14
3.1.4 Prognosis 14
3.1.5 Quality of Life 15
3.2 Symptoms 15
4 Disease Management 17
4.1 Overview 17
4.1.1 Diagnosis Overview 17
4.1.2 Treatment Guidelines 19
4.1.3 Treatment Overview 24
4.2 India 27
4.2.1 Diagnosis 27
4.2.2 Clinical Practice 27
5 Competitive Assessment 29
5.1 Overview 29
5.2 Strategic Competitor Assessment 29
5.3 Product Profiles – Major Brands 31
5.3.1 Restasis (cyclosporine 0.05% ophthalmic emulsion) 31
5.3.2 Additional Therapies 35
6 Opportunity and Unmet Need 39
6.1 Overview 39
6.2 Diagnostic tests are not specific enough to identify subgroups of patients 40
6.3 Frequent dosing and side effects limit compliance 41
6.4 Lack of physician and patient awareness 42
6.5 Trial design may be a factor in so few drugs being approved 43
6.6 Unmet Needs Gap Analysis 44
6.7 Comprehensive method for measuring dry eye signs and severity levels 45
6.8 Increase treatment rates among milder forms of the disease 46
7 Pipeline Assessment 47
7.1 Overview 47
7.2 Promising drugs in clinical development 48
8 Market Outlook 50
8.1 India 50
8.1.1 Forecast 50
8.1.2 Key Events 51
8.1.3 Drivers and Barriers 52
9 Appendix 53
9.1 Bibliography 53
9.2 Abbreviations 56
9.3 Methodology 58
9.4 Forecasting Methodology 58
9.4.1 Diagnosed DES patients 58
9.4.2 Percent Drug-treated Patients 59
9.4.3 Drugs Included in Each Therapeutic Class 59
9.4.4 General Pricing Assumptions 59
9.4.5 Individual Drug Assumptions 60
9.5 Physicians and Specialists Included in this Study 61
9.6 About the Authors 62
9.6.1 Author 62
9.6.2 Global Head of Healthcare 63
9.7 About GlobalData 64
9.8 Contact Us 64
9.9 Disclaimer 64
1.1 List of Tables
Table 1: Symptoms of Dry Eye Syndrome 16Table 2: Treatment Guidelines for Dry Eye Syndrome 24Table 3: Commonly Prescribed Drugs for Dry Eye Syndrome by Class in the Global Markets, 2012 26Table 4: Leading Treatments for Dry Eye Syndrome, 2012 30Table 5: Product Profile – Restasis 32Table 6: Restasis SWOT Analysis, 2012 35Table 7: Summary of Minor Drug Classes, 2012 38Table 8: Overall Unmet Needs – Current Level of Attainment 40Table 9: Clinical Unmet Needs – Gap Analysis, 2012 45Table 10: Dry Eye Syndrome – Phase Pipeline, 2012 48Table 11: Comparison of Therapeutic Classes in Development for Dry Eye Syndrome, 2012 49Table 12: Sales Forecasts ($m) for Dry Eye Syndrome in India, 2012–2022 50Table 13: Key Events Impacting Sales for Dry Eye Syndrome in India, 2012–2022 51Table 14: India, Dry Eye Syndrome Market – Drivers and Barriers, 2012-2022 52
1.2 List of Figures
Figure 2: Tear Film in Normal Eye and Dry Eye 12
Figure 3: Sequence of Diagnostic Tests Used to Diagnose Dry Eye Syndrome 17
Figure 4: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome Without Lid Margin Disease, 2006 20
Figure 5: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome With Lid Margin Disease and Abnormal Tear Distribution, 2006 21
Figure 6: Treatment Recommendations for Dry Eye Syndrome from the Management and Therapy Subcommittee, Dry Eye Workshop, 2007 22
Figure 7: American Academy of Ophthalmology Preferred Practice Pattern for Dry Eye, 2011 23
Figure 8: Competitive Assessment of Late-Stage Pipeline Agents in Dry Eye Syndrome, 2012–2022 48
Figure 9: Sales for Dry Eye Syndrome in India by Drug Class, 2012–2022 51
To order this report: PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022http://www.reportlinker.com/p01622995/PharmaPoint-Dry-Eye-Syndrome---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article